Advertisement
Advertisement

ENLV

ENLV logo

Enlivex Therapeutics Ltd. Ordinary Shares

0.92
USD
Sponsored
+0.08
+10.04%
Jan 09, 14:01 UTC -5
Open

ENLV Earnings Reports

Positive Surprise Ratio

ENLV beat 17 of 29 last estimates.

59%

Next Report

Date of Next Report
Mar 30, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.11
Implied change from Q3 25 (Revenue/ EPS)
--
/
+22.22%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-52.17%

Enlivex Therapeutics Ltd. Ordinary Shares earnings per share and revenue

On Nov 14, 2025, ENLV reported earnings of -0.09 USD per share (EPS) for Q3 25, beating the estimate of -0.12 USD, resulting in a 26.47% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.63% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.11 USD, with revenue projected to reach -- USD, implying an increase of 22.22% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
Dec 26, 2025 For Q4 25
Estimate
-$0.49
Actual
-
Surprise
-
FAQ
For Q3 2025, Enlivex Therapeutics Ltd. Ordinary Shares reported EPS of -$0.09, beating estimates by 26.47%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.63%, changed from $0.99 before the earnings release to $0.98 the day after.
The next earning report is scheduled for Mar 30, 2026.
Based on 3 analysts, Enlivex Therapeutics Ltd. Ordinary Shares is expected to report EPS of -$0.11 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement